27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- IN8bio Inc (NASDAQ:INAB) announced the ability of its non-signaling gamma-delta CAR-T platform (nsCAR) to target leukemic cells while preserving healthy B cells selectively.
- IN8bio's nsCAR platform uses the innate immune recognition of gamma-delta T cells to distinguish between tumor and healthy tissue, offering a targeted but potentially less toxic approach.
- Also Read: With Over 400% Upside, This Cancer Stock Offers 'Attractive Entry Point To Long-Term Investors,' Analyst Says.
- In a 48-hour in vitro cytotoxicity experiment, the nsCAR platform demonstrated a greater than 15x difference in killing between leukemic cells and healthy B cells (79.7% versus 5.2%) when both express the CD19 target antigen.
- The nsCAR platform is also engineered to express the cytokine interleukin-15 (IL-15) to enhance cellular persistence and the ability to target and kill tumor cells over time.
- The platform can potentially broaden CAR technology's utilization for previously "undruggable" solid and liquid tumor targets, the company said.
- Price Action: INAB shares are down 12.77% at $1.57 on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!